Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and ge...
Saved in:
Main Authors: | Sara Salvador-Martín, Alejandra Melgarejo-Ortuño, Luis A. López-Fernández |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/b275a7c3d7d14dff9e7bd172375fb3fe |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
by: David Ternant, et al.
Published: (2021) -
Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review
by: Laila Aldars-García, et al.
Published: (2021) -
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved
by: Luis G. Guijarro, et al.
Published: (2021) -
A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
by: Byron P. Vaughn
Published: (2021) -
Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin
by: Cao Y, et al.
Published: (2021)